NCT03498183 (MIBI-THYR) is a Phase 2, PHASE3 clinical trial of MIBI-Tc99m/Iodine-123 in Malignancy of Thyroid Nodules, sponsored by Nantes University Hospital.

Who is sponsoring NCT03498183?

NCT03498183 is sponsored by Nantes University Hospital.

What drugs are being tested in NCT03498183?

Interventions in NCT03498183: MIBI-Tc99m/Iodine-123.

What condition does NCT03498183 study?

NCT03498183 studies Malignancy of Thyroid Nodules.

Is NCT03498183 still recruiting?

NCT03498183 is currently completed. Last updated 6 June 2025.

Last reviewed 2025-06-06 · How we verify

NCT03498183: MIBI-THYR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology

Completed Phase 2, PHASE3 Last updated 6 June 2025

What this trial tests

Phase 2, PHASE3 trial testing MIBI-Tc99m/Iodine-123 in Malignancy of Thyroid Nodules in 372 participants. Completed in 7 May 2025.

Timeline

17 January 2019

Primary endpoint
7 May 2025

7 May 2025

Quick facts

Lead sponsor	Nantes University Hospital
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	372
Start date	17 January 2019
Primary completion	7 May 2025
Estimated completion	7 May 2025
Sites	7 locations across France

Drugs / interventions tested

MIBI-Tc99m/Iodine-123 — full drug profile →

Conditions studied

Malignancy of Thyroid Nodules — all drugs for Malignancy of Thyroid Nodules →

Sponsor

Nantes University Hospital

Who can join

18 and older, any sex, with Malignancy of Thyroid Nodules. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of the study is to show that the addition of ultrasonography to the dual tracer scintigraphy MIBI-Tc99m/Iodine-123 will increase (at least +5%) the negative predictive value compared to the dual tracer scintigraphy alone in detection of malignancy in thyroid nodules ≥15 mm classified as Bethesda III-IV on cytology.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Nantes University Hospital trials

Trials by the same sponsor.

NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03498183 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
Last refreshed: 6 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03498183.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing